# A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor

> **NCT06245018** · NA · NOT_YET_RECRUITING · sponsor: **Nuwacell Biotechnologies Co., Ltd.** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** iNK Injection

## Key facts

- **NCT ID:** NCT06245018
- **Lead sponsor:** Nuwacell Biotechnologies Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06245018

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06245018, "A Trial to Evaluate the Safety and Preliminary Efficacy of iNK in the Treatment of Subjects With Solid Tumor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06245018. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*